Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Jul 01, 2019 12:46pm

223 Views

Post# 29878295

RE:RE:RE:Interesting Article - Huge Potential

Been in this puppy since 2003. Made a fair return trading it, but always kept a fair number in the vault. It was estimated a few years ago that the value of ONC's myriad of patents and discoveries was worth about $1B to a big Pharma. Notwithstanding any positive results from current studies, that would put the true value of ONC at just under $50/share, or $5.25/share pre reverse split.

Bullboard Posts

Rising miner increases graphite price, restarts Québec mill